tbuckley/cabot-search huggingface dataset:
Do the 2019 EULAR/ACR SLE classification criteria close the door on certain groups of SLE patients?
Authors: Huihui Chi, Jialin Teng, Zhihong Wang, Chengde Yang, Yutong Su
Journal: Annals of the Rheumatic Diseases (2019)

Do the 2019 EULAR/ACR SLE classification criteria close the door on certain groups of SLE patients?The release of the 2019 EULAR/ACR classification criteria of SLE would be considered a landmark work in developing international consensus on SLE classification criteria. 1However, there are some concerns regarding the new criteria.First of all, the criteria did not include clinical manifestations sometimes could occur as initial symptoms in SLE patients.If a patient comes to a rheumatologist with the only presentation, such as repeated vascular thrombosis, mesenteric vasculitis or unexplained liver injury and positive results for both antinuclear antibodies and antibodies to the double-stranded DNA, would they be classified as SLE?With the increasing understanding of the aetiology and pathogenesis of SLE and the continuous development of the testing technique, the updated classification criteria of SLE included complement proteins and more antibodies. [1]][3][4] However, the clinical domains of the criteria were not substantially updated.Besides, the non-SLE populations used for the derivation and validation cohorts were mainly other rheumatic disorders and infection except malignancies.Malignancies, especially haematological tumours, could sometimes mimic SLE-like symptoms, and misdiagnosis would delay the treatments, which were contributing to a growing quandary for clinical decisionmaking.It would be more practicable if patients with malignancies such as lymphoma were included in the non-SLE groups during the derivation and validation process.What is more, it would be interesting if the authors could show the performance of the criteria in different age groups, sex and ethnicity as the authors pointed out that the derivation and validation cohorts were from limited populations and needed to be further validated among different groups.
Two proposed bills aim to cut drug costs for retired Americans
Authors: Janice Hopkins Tanne
Journal: BMJ (2019)

Two proposed bills suggest ways to reduce the high cost of prescription drugs, primarily for the 44 million retired Americans who rely on Medicare health insurance.

High drug costs are a concern for many Americans, particularly for retired people who are more likely to take prescription drugs. Despite having Medicare insurance, they pay part of a prescription’s cost, called a co-pay. Drug costs have increased at double the rate of inflation, or more. Prices for some drugs are as much as seven times their cost in other industrialised countries. Surveys have shown that because of the cost some older Americans are not filling prescriptions, are cutting a dose in half, or skipping a dose.

Medicare beneficiaries can choose optional insurance (called a Plan D Medicare Prescription Drug plan) to help cover their prescription expenses. Until this year beneficiaries had a gap in coverage, called a donut hole, during which the beneficiary paid more for their drugs before reaching catastrophic coverage, …
Pediatric Reference Intervals for the DxH 520* Hematology Analyzer
Authors: Astrid C Smit, Aprille Lynn Seidel, Justin Rohrbach, Robert Magari, Karen Lo, Javier Martin, Khosrow Adeli, Victoria Higgins, Meer-Taher Shabani-Rad, Maureen Cyfra, Tracey Gwilliam, Wendy Michaud, Brian Tuson, Kristy Schmitt, Nicole Couvrette, Sandra Axelson, Liliana M. Tejidor
Journal: Blood (2018)
Forced and Coerced Sexual Initiation in Women
Authors: Alison J. Huang, Carolyn J. Gibson
Journal: JAMA Internal Medicine (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
ATS Health Alert—Vaping-associated Pulmonary Illness (VAPI)
Authors: W. Graham Carlos, Laura E. Crotty Alexander, Jane E. Gross, Charles S. Dela Cruz, Jonathan M. Keller, Susan Pasnick, Shazia Jamil
Journal: American Journal of Respiratory and Critical Care Medicine (2019)

"ATS Health Alert—Vaping-associated Pulmonary Illness (VAPI)." American Journal of Respiratory and Critical Care Medicine, 200(7), p. P15
Comparing Warfarin With Aspirin After Biological Aortic Valve Replacement
Authors: TizianoGherli, AndreaColli, ClaudioFragnito, FrancescoNicolini, BrunoBorrello, StefanoSaccani, RobertoD’Amico, CesareBeghi
Journal: Circulation (2004)

Background— Patients with prosthetic heart valves have a higher risk of developing valve thrombosis and arterial thromboembolism. Antithrombotic therapy in the early postoperative period after biological aortic valve replacement (BAVR) is controversial. The American College of Cardiology/American Heart Association and European Society of Cardiology guidelines recommend the use of warfarin for the first 3 months after BAVR, although the American College Chest Physician guidelines suggest that the recommendations are very weak and that the risk/benefit is unclear. This prospective study investigated the efficacy of postoperative warfarin compared with aspirin in patients after aortic valve replacement. Methods and Results— Patients undergoing BAVR between 2001 and 2002 received 2 antithrombotic therapies: 141 patients received warfarin for the first 3 months, and 108 patients received only aspirin. The major end points evaluated were the rate of cerebral ischemic events, bleeding, and survival. There were 3...
Polyurethane End‐Capped by Tetramethylpyrazine‐Nitrone for Promoting Endothelialization Under Oxidative Stress
Authors: Baoliu Qu, Liguang Yuan, Lei Yang, Jinge Li, Hongying Lv, Xiaoniu Yang
Journal: Advanced Healthcare Materials (2019)

Abstract Thrombus and restenosis are two main factors that cause the failure of vascular implants. Constructing a functional and confluent layer of endothelial cells (ECs) is considered an ideal method to prevent these problems. However, oxidative stress induced by the disease and implantation can damage ECs and hinder the endothelialization of implants. Thus, developing biomaterials that can protect ECs adhesion and proliferation from oxidative stress is urgently needed for the rapid endothelialization of vascular implants. In this work, a novel polyurethane (PU‐TBN) is synthesized by employing tetramethylpyrazine‐nitrone (TBN) as end‐group to endow polymers with dual functions of antioxidant activity and promoting endothelialization. Common PU without TBN is also prepared to be control. Compared to PU, PU‐TBN significantly promotes human umbilical vein endothelial cells (HUVECs) adhesion and proliferation, where cells spread well and a confluent endothelial layer is formed. PU‐TBN also shows obvious free radical scavenging activity, and thus effectively attenuates oxidative stress to protect HUVECs from oxidative apoptosis. Moreover, PU‐TBN exhibits enhanced antiplatelets effect, excellent biocompatibility, and similar mechanical properties to PU. These characteristics can endow PU‐TBN with great potential to be used as vascular implants or coatings of other materials for rapid endothelialization under complex oxidative stress environment.
Genetic polymorphisms of EGF 5'-UTR in patients with glioma: A possible predictive marker of outcome.
Authors: Emanuela Vattemi, Giovanna Cipollini, Cristina Dealis, Lorena Rossi, Susanne Baier, Elisabetta Cretella, Giovanni Di Meglio, Valentina Sini, Maria Rita Lusso, Roberta Ruda, Marija Petric, Claudio Graiff
Journal: Journal of Clinical Oncology (2013)

e13009 Background: Epidermal growth factor (EGF) plays an important role in carcinogenesis. An adenine (A) to guanine (G) single nucleotide polymorphism at position 61 in the 5'-untranslated region (5'-UTR) of the EGF gene has been found to be associated with levels of EGF production and contribute to the risk of glioma. However, published data are contradictory. EGF +61G/A polymorphism may contribute to the risk of glioma in different ethnic group. Patients with glioma and GG genotype have been reported to have a risk of poorer otucome than patients with AA genotype. Purpose of this study is to investigate the potential role of this polymorphism in cancer progression and its role as predictive marker of outcome in glioma caucasian patients. Methods: EGF 61A/G polymorphism (rs4444903) was analyzed in glioma patients and was determined by means of Polymerase Chain Reaction and Direct Sequencing method (GenBank reference sequence-accession no. AC005509) from blood samples. Association of this genetic polymorphism with clinical and pathological data of patients was evaluated. Results: We investigated EGF +61G/A polymorphism in 24 glioma patients . EGF +61G allele has been found in 67% of glioma patients (25% G/G genotype and 42% A/G genotype). In astrocytomas, EGF +61G allele represents a 83% frequency; in glioblastomas and in oligodendrogliomas, EGF +61G allele frequency represents respectively 71% and 50%. In WHO IV gliomas, the EGF +61G allele represents a 63% frequency, (27% G/G and 36% A/G ), in WHO III gliomas a 77% frequency (33% G/G and 44% A/G ) and in WHO II gliomas a 50% frequency (100% A/G ). Median PFS of glioblastoma patients was 9 months. 83% of glioblastoma patients with a relapsing disease showed the G/G and A/G genotype. No difference was detected in the others histotypes. Conclusions: Our data conferm previous studies which reported G allele as a risk factor for glioma in Caucasian. G/A and G/G genotypes seem to be more rappresentative in high grade gliomas . Despite limited number of patients, our study supports the predictive role of EGF 61 A/G polymorphism in GBM. Additional large studies are warranted to confirm the role of EGF polymorphism as indipendent prognostic factor in glioma.
High-Risk Human Papillomavirus Infection and the Risk of Cardiovascular Disease in Korean Women
Authors: Eun-Jeong Joo, Yoosoo Chang, Min-Jung Kwon, Ara Cho, Hae Suk Cheong, Seungho Ryu
Journal: Circulation Research (2019)

Until now, no cohort studies have evaluated the relationship between high-risk human papillomavirus (HPV) infection and new-onset cardiovascular diseases (CVD).We investigated an association between high-risk HPV infection and the development of CVD.We conducted a cohort study of 63 411 women aged 30 or older without CVD at baseline who underwent a high-risk HPV test and were followed annually or biennially from 2011 to 2016. CVD was ascertained through the linkage to the Health Insurance and Review Agency database. A Cox-proportional hazards regression model was used to estimate adjusted hazard ratios (HRs) with 95% CIs of incident CVD. The prevalence of high-risk HPV infection was 7.6%. During 261 598.9 person-years of follow-up, 1122 cases of new-onset CVD were identified (incidence rate of 4.3 per 103 person-years). High-risk HPV infection was significantly associated with incident CVD. After adjustment for possible confounders, and high sensitivity C-reactive protein, a significant association between high-risk HPV infection and incident CVD was still observed, with a corresponding HR (95% CI) of 1.25 (1.03-1.52). This association was stronger among individuals with obesity and those with metabolic syndrome. Multivariable-adjusted HR (95% CI) for incident CVD comparing high-risk HPV-positive- to high-risk HPV-negative participants was 1.10 (0.87-1.39) in the nonobese, whereas corresponding HR (95% CI) was 1.73 (1.19-2.51) in those with obesity ( P for interaction by obesity=0.02). Similarly, multivariable-adjusted HR (95% CI) for incident CVD comparing high-risk HPV-positive- to high-risk HPV-negative participants was 1.09 (0.87-1.36) in those without metabolic syndrome and 1.99 (1.28-3.08) in those with MetS ( P for interaction=0.05).In this large cohort, high-risk HPV infection was significantly associated with an increased risk of developing CVD, especially in obese individuals and those with MetS, indicating that high-risk HPV might affect CVD risk with possible effect modification by obesity and MetS.
Safety and efficacy of the partial adenosine A1 receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced ejection fraction: a phase IIb, randomized, double‐blind, placebo‐controlled trial
Authors: Adriaan A. Voors, Jeroen J. Bax, Adrian F. Hernandez, Antonieta B. Wirtz, Akos F. Pap, Anna C. Ferreira, Michele Senni, Michael van der Laan, Javed Butler
Journal: European Journal of Heart Failure (2019)

Neladenoson bialanate is a partial adenosine A1 receptor agonist with demonstrated beneficial effects on cardiac function in animal models. We aimed to assess the dose-response effect of neladenoson bialanate on cardiac structure and function, clinical outcome, and safety in patients with heart failure (HF) with reduced ejection fraction (HFrEF).PANTHEON was a dose-finding, phase IIb, randomized, double-blind, placebo-controlled trial conducted in 92 centres in 11 countries including 462 patients with chronic HFrEF, randomized to once daily oral dose of neladenoson bialanate (5, 10, 20, 30, and 40 mg) or placebo. The primary endpoints were change from baseline to 20 weeks in left ventricular ejection fraction (LVEF) (echocardiography) and in N-terminal pro-B-type natriuretic peptide (NT-proBNP). Mean age of the patients was 67 years, 17% were female, mean LVEF was 28%, mean NT-proBNP was 2085 ng/L. After 20 weeks of treatment, there was no dose-effect of neladenoson bialanate on changes in NT-proBNP or LVEF (primary endpoints). No effect of neladenoson bialanate was found on left ventricular volumes, high-sensitivity troponin T, or cardiovascular mortality, HF hospitalization, and urgent visits for HF (secondary endpoints). There was a dose-dependent increase in creatinine and cystatin C, and a dose-dependent decrease in estimated glomerular filtration rate and heart rate.In patients with chronic HFrEF, treatment with neladenoson bialanate was not associated with dose-dependent favourable effects on cardiac structure and function, cardiac risk markers, or clinical outcome but was associated with a dose-dependent decrease in renal function.ClinicalTrials.gov Identifier NCT02992288.
Role of ANA testing in the classification of patients with systemic lupus erythematosus
Authors: David S Pisetsky, Diane M Spencer, Brad Rovin, Peter E Lipsky
Journal: Annals of the Rheumatic Diseases (2019)

The recent publication1 2 of the European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) criteria for the classification for systemic lupus erythematosus (SLE) provides an important reason to continue the dialogue on testing for antinuclear antibodies (ANA) that has appeared in Annals of the Rheumatic Diseases ( ARD ). Following our article on the variability of immunofluorescence assays (IFA) for testing ANA in SLE,3 the journal published a series of very interesting and informative letters addressing our findings and reporting on other experience in ANA testing.4–12 These letters have been important in alerting the field to the challenges in ANA testing and the variety of assay approaches, including solid phase assays (SPA), that are currently available for determining the serological status of patients.

While our focus was the clinical trial setting, our results are also relevant to the new classification criteria.1 2 These criteria differ from previous classification systems in the positioning of a positive ANA. Whereas a positive ANA represented one criterion in the ACR and Systemic Lupus International Collaborating Clinics criteria,13 14 in the new EULAR/ACR criteria, a positive ANA is necessary for classification; if this criterion is met, other manifestations receive varying numbers of points to determine classification. Such a positioning implies that SLE is always ANA positive, that a negative ANA can …
Multidrug-Resistant Malaria Expands its Reach
Authors: Bridget Kuehn
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Collapsin Response-Mediator Protein 5–Associated Retinitis, Vitritis, and Optic Disc Edema
Authors: Devon A. Cohen, M. Tariq Bhatti, Jose S. Pulido, Vanda A. Lennon, Divyanshu Dubey, Eoin P. Flanagan, Sean J. Pittock, Christopher J. Klein, John J. Chen
Journal: Ophthalmology (2019)
Association of multivitamin and alcohol intake with folate receptor alpha (FRα) expression in a case-control study of ovarian cancer
Authors: Linda E. Kelemen, Thomas A. Sellers, Gary L. Keeney, Wilma L. Lingle, Lynn C. Hartmann
Journal: Cancer Research (2005)

5819  Background FRα overexpression in epithelial ovarian cancer (EOC) may confer a tumor growth advantage. We examined the relation between multivitamin use, a proxy for folic acid intake, with FRα expression in ovarian tumors and assessed whether the association was modified by alcohol intake, a folate agonist. Methods Cases (n=148) aged 20-80 years were seen at Mayo Clinic, MN between 1/00 and 8/04 with suspected EOC. Controls (n=148) without history of cancer and both ovaries intact were frequency matched to cases by age (5 years) and state. Lifestyle, medical and reproductive factors, regular multivitamin (≥ 4 pills per week) and weekly alcohol (≥ 5 vs
A perturbed gene network containing PI3K–AKT, RAS–ERK and WNT–β-catenin pathways in leukocytes is linked to ASD genetics and symptom severity
Authors: Vahid H. Gazestani, Tiziano Pramparo, Srinivasa Nalabolu, Benjamin P. Kellman, Sarah Murray, Linda Lopez, Karen Pierce, Eric Courchesne, Nathan E. Lewis
Journal: Nature Neuroscience (2019)
Flow cytometric detection of leukemic blasts in cerebrospinal fluid predicts risk of relapse in childhood acute lymphoblastic leukemia: a Nordic Society of Pediatric Hematology and Oncology study
Authors: Maria Thastrup, Hanne Vibeke Marquart, Mette Levinsen, Kathrine Grell, Jonas Abrahamsson, Birgitte Klug Albertsen, Thomas Leth Frandsen, Arja Harila-Saari, Päivi Maria Lähteenmäki, Riitta Niinimäki, Cornelis Jan Pronk, Aina Ulvmoen, Goda Vaitkevičienė, Mervi Taskinen, Kjeld Schmiegelow, Peder Wehner, Britt-Marie Frost, Ulrika Norén-Nyström, Mikael Behrendtz, Bendik Lund, Jouni Pesola, Dorota Malgorzata Wojcik
Journal: Leukemia (2019)
Ezetimibe Lipid-Lowering Trial on Prevention of Atherosclerotic Cardiovascular Disease in 75 or Older (EWTOPIA 75)
Authors: Yasuyoshi Ouchi, Jun Sasaki, Hidenori Arai, Koutaro Yokote, Kazumasa Harada, Yasuo Katayama, Takao Urabe, Yasufumi Uchida, Masaru Hayashi, Naoto Yokota, Hirokazu Nishida, Takatoshi Otonari, Tadashi Arai, Ichiro Sakuma, Kazuo Sakabe, Masayasu Yamamoto, Takashi Kobayashi, Shinichi Oikawa, Shizuya Yamashita, Hiromi Rakugi, Takumi Imai, Shiro Tanaka, Yasuo Ohashi, Masanari Kuwabara, Hideki Ito
Journal: Circulation (2019)

Background: Evidence regarding the primary prevention of coronary artery disease events by low-density lipoprotein cholesterol (LDL-C) lowering therapy in older individuals, aged ≥75 years, is insufficient. This trial tested whether LDL-C–lowering therapy with ezetimibe is useful for the primary prevention of cardiovascular events in older patients. Methods: This multicenter, prospective, randomized, open-label, blinded end-point evaluation conducted at 363 medical institutions in Japan examined the preventive efficacy of ezetimibe for patients aged ≥75 years, with elevated LDL-C without history of coronary artery disease. Patients, who all received dietary counseling, were randomly assigned (1:1) to receive ezetimibe (10 mg once daily) versus usual care with randomization stratified by site, age, sex, and baseline LDL-C. The primary outcome was a composite of sudden cardiac death, myocardial infarction, coronary revascularization, or stroke. Results: Overall, 3796 patients were enrolled between May 2009 and December 2014, and 1898 each were randomly assigned to ezetimibe versus control. Median follow-up was 4.1 years. After exclusion of 182 ezetimibe patients and 203 control patients because of lack of appropriate informed consent and other protocol violations, 1716 (90.4%) and 1695 (89.3%) patients were included in the primary analysis, respectively. Ezetimibe reduced the incidence of the primary outcome (hazard ratio [HR], 0.66; 95% CI, 0.50–0.86; P =0.002). Regarding the secondary outcomes, the incidences of composite cardiac events (HR, 0.60; 95% CI, 0.37–0.98; P =0.039) and coronary revascularization (HR, 0.38; 95% CI, 0.18–0.79; P =0.007) were lower in the ezetimibe group than in the control group; however, there was no difference in the incidence of stroke, all-cause mortality, or adverse events between trial groups. Conclusions: LDL-C–lowering therapy with ezetimibe prevented cardiovascular events, suggesting the importance of LDL-C lowering for primary prevention in individuals aged ≥75 years with elevated LDL-C. Given the open-label nature of the trial, its premature termination and issues with follow-up, the magnitude of benefit observed should be interpreted with caution. Clinical Registration: URL: https://www.umin.ac.jp . Unique identifier: UMIN000001988.
ACC/AHA guidelines for the management of patients with unstable angina and non–st-segment elevation myocardial infarction
Authors: Eugene Braunwald, Elliott M Antman, John W Beasley, Robert M Califf, Melvin D Cheitlin, Judith S Hochman, Robert H Jones, Dean Kereiakes, Joel Kupersmith, Thomas N Levin, Carl J Pepine, John W Schaeffer, Earl E Smith, David E Steward, Pierre Theroux, Raymond J Gibbons, Joseph S Alpert, Kim A Eagle, David P Faxon, Valentin Fuster, Timothy J Gardner, Gabriel Gregoratos, Richard O Russell, Sidney C Smith
Journal: Journal of the American College of Cardiology (2000)